Marksans Pharma Limited (IN:MARKSANS)
:MARKSANS
Want to see IN:MARKSANS full AI Analyst Report?
Top Page
Marksans Pharma Limited
(MARKSANS)
Select Model
Select Model
Rating:75Outperform
Price Target:
₹284.00
▲(56.00% Upside)
Action:Reiterated
Date:06/10/26
The score is driven primarily by solid fundamentals (steady growth, good profitability, and low leverage), supported by strong technical uptrend signals. The main restraint is valuation, with a higher P/E and very low dividend yield, plus some risk from recent margin compression and uneven historical cash-flow consistency.
Positive Factors
Revenue Growth
Sustained multi-year top-line growth indicates successful product penetration and geographic diversification in generics. A steady revenue base supports investments in scale, regulatory compliance and new product introductions, reducing reliance on any single market or short-term pricing cycles.
Negative Factors
Gross Margin Compression
A sharp drop in gross margin signals structural pressure from input costs, pricing erosion, or adverse product mix. If sustained, this directly reduces operating leverage and free cash generation, forcing either cost cutting, price increases or margin dilution across product lines.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained multi-year top-line growth indicates successful product penetration and geographic diversification in generics. A steady revenue base supports investments in scale, regulatory compliance and new product introductions, reducing reliance on any single market or short-term pricing cycles.
Read all positive factors
Marksans Pharma Limited (MARKSANS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹113.13B
Dividend Yield0.44%
Average Volume (3M)99.03K
Price to Earnings (P/E)27.4
Beta (1Y)1.36
Revenue Growth12.51%
EPS Growth9.82%
CountryIN
Employees1,141
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)7.77
Shares Outstanding453,163,760
10 Day Avg. Volume119,310
30 Day Avg. Volume99,030
Financial Highlights & Ratios
PEG Ratio1.74
Price to Book (P/B)2.35
Price to Sales (P/S)2.41
P/FCF Ratio20.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.33
Revenue Forecast (FY)₹34.41B
Marksans Pharma Limited Business Overview & Revenue Model
Company Description
Marksans Pharma Limited, along with its subsidiaries, operates internationally, engaging in the full spectrum of generic pharmaceutical formulation activities, from research and development and manufacturing to marketing, distribution, and sales. ...
How the Company Makes Money
Marksans Pharma Limited makes money primarily by selling generic pharmaceutical products. Its revenue model is based on (1) product sales in domestic and export markets, where revenues are recognized from the shipment/sale of finished dosage-form ...
Marksans Pharma Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.31B | 29.51B | 26.23B | 21.77B | 18.52B | 14.80B |
| Gross Profit | 15.37B | 11.57B | 14.79B | 11.03B | 9.31B | 7.32B |
| EBITDA | 5.62B | 6.03B | 5.29B | 5.09B | 3.99B | 3.01B |
| Net Income | 3.52B | 4.18B | 3.81B | 3.14B | 2.66B | 1.85B |
Balance Sheet | ||||||
| Total Assets | 34.42B | 38.61B | 32.40B | 26.81B | 21.90B | 16.40B |
| Cash, Cash Equivalents and Short-Term Investments | 6.71B | 9.90B | 7.05B | 7.00B | 7.19B | 3.47B |
| Total Debt | 3.32B | 3.43B | 3.22B | 2.44B | 1.23B | 1.11B |
| Total Liabilities | 7.28B | 8.08B | 7.50B | 5.95B | 4.25B | 4.17B |
| Stockholders Equity | 26.88B | 30.23B | 24.67B | 20.65B | 17.45B | 12.02B |
Cash Flow | ||||||
| Free Cash Flow | 19.97M | 3.51B | 337.45M | 215.69M | 1.84B | 529.27M |
| Operating Cash Flow | 751.86M | 4.82B | 2.07B | 2.30B | 2.37B | 992.57M |
| Investing Cash Flow | -364.77M | -2.75B | -490.09M | -1.41B | -2.59B | -416.86M |
| Financing Cash Flow | -528.77M | -681.43M | -651.46M | -687.27M | 1.98B | 795.11M |
Marksans Pharma Limited Technical Analysis
Positive
182.05
Price Trends
204.10
Positive
188.23
Positive
184.28
Positive
Market Momentum
13.18
Positive
67.10
Neutral
67.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MARKSANS, the sentiment is Positive. The current price of 182.05 is below the 20-day moving average (MA) of 234.45, below the 50-day MA of 204.10, and below the 200-day MA of 184.28, indicating a bullish trend. The MACD of 13.18 indicates Positive momentum. The RSI at 67.10 is Neutral, neither overbought nor oversold. The STOCH value of 67.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MARKSANS.
Marksans Pharma Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹113.13B | 27.36 | ― | 0.44% | 12.51% | 9.82% | |
71 Outperform | ₹379.85B | 36.27 | ― | 1.07% | 14.50% | 47.08% | |
71 Outperform | ₹72.44B | 23.20 | ― | 4.73% | -12.98% | -21.81% | |
69 Neutral | ₹1.12T | 28.92 | ― | 0.87% | 2.23% | -26.44% | |
69 Neutral | ₹356.21B | 34.70 | ― | 2.16% | 1.93% | 11.69% | |
64 Neutral | ₹209.18B | 28.55 | ― | 0.69% | 10.45% | -5.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:MARKSANS
Marksans Pharma Limited
252.15
-4.99
-1.94%
IN:CIPLA
Cipla Ltd
1,388.80
-107.90
-7.21%
IN:GLAND
Gland Pharma Ltd.
2,261.10
508.38
29.01%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,120.70
-1,162.41
-35.41%
IN:PFIZER
PFIZER LIMITED
4,509.90
-1,198.12
-20.99%
IN:SANOFI
Sanofi India Limited
3,119.95
-2,846.26
-47.71%
Marksans Pharma Limited Corporate Events
Marksans Pharma Gets Positive Outlook From India Ratings on Bank Loans
Jun 9, 2026
Marksans Pharma Limited said India Ratings and Research, part of the Fitch Group, has revised the outlook on its bank loan facilities to Positive from Stable while affirming the existing ratings. The revised outlook on the ₹195.75 crore faci...
Marksans Pharma Posts Q4 FY26 Earnings Call Audio for Investors
May 27, 2026
Marksans Pharma Limited has notified stock exchanges that it has uploaded the audio recording of its investor and analyst conference call discussing Q4 FY26 financial results to its website. The disclosure, made under SEBI’s listing regulati...
Marksans Pharma Releases Q4 and FY26 Investor Presentation
May 26, 2026
Marksans Pharma Limited has released its investor presentation for the fourth quarter and full year FY26, in line with disclosure requirements under SEBI listing regulations. The presentation, shared with stock exchanges BSE and NSE, provides inve...
Marksans Pharma Delivers Record FY26 Revenue, Profit and Strong Global Expansion
May 26, 2026
Marksans Pharma reported a milestone FY26, achieving its highest-ever total income of about ₹3,033 crore, EBITDA of ₹601 crore with a 20.4% margin, and record profit after tax of ₹420 crore, in line with earlier guidance. Managem...
Marksans Pharma to Join Investec India Promoter & Founder Conference 2026
Mar 10, 2026
Marksans Pharma Limited has notified the stock exchanges that its officials will participate in the Investec India Promoter Founder Conference 2026, scheduled for March 11, 2026, as a physical event at the Trident BKC in Mumbai. The company clari...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.